🔗 Share this article US and UK Strike Duty-Free Arrangement on Pharmaceuticals. Stock image of drug trade. The United Kingdom and the United States have concluded a important bilateral deal that will ensure zero tariffs on UK pharmaceutical shipments being sold in the American market. The Terms of the Accord As part of the deal, the UK has agreed to boost expenditure on medicines through the NHS. This move ensures that import taxes on these key exports will stay at zero for a duration of 36 months. This deal follows earlier threats to dramatically increase import taxes on patented pharmaceutical products, with potential rates mentioned reaching double the cost. "This agreement between the UK reinforces the global environment for innovative medicines and establishes long-overdue balance to American-British medicine commerce," a release said. Trade Impact Medicines constitute one of the Britain's largest exports to the United States, which is by far the biggest buyer for large UK drugmakers. Export figures reveal that in the year to the end of September, the UK exported drugs valued at over eleven billion pounds to the US. This figure made up nearly one-fifth of British export trade in that period. "This deal safeguards employment, stimulates funding and paves the way for the UK to emerge as a international leader for biotech and pharma," a government official stated. Detailed UK Commitments The pact entails several notable changes from the British government: Revised Affordability Limit: The UK will raise the price threshold at which it judges new treatments to be prohibitively costly by 25%. Higher Drug Budget: There is a target to double overall NHS spending on drugs from 0.3% of GDP to 0.6% over the following ten-year period. Rebate Cap: The sum pharmaceutical firms must pay back to the NHS to control costs will be capped at 15%. In the past, rebates topped 20%. Broader Context This agreement comes amid a ongoing dispute between the sector and the UK government over medicine costs and regulatory access. These tensions were exacerbated by assertions that American customers were charged significantly more for the equivalent treatments than consumers in the UK and Europe. Recently, several major manufacturing plans in the UK have been delayed or scrapped, while major funding commitments have been announced toward US facilities. A senior figure publicly accepted that the NHS had to invest a greater share on treatments, noting that its budget allocation on drugs had shrunk as a percentage of its overall budget over the last ten years.
Stock image of drug trade. The United Kingdom and the United States have concluded a important bilateral deal that will ensure zero tariffs on UK pharmaceutical shipments being sold in the American market. The Terms of the Accord As part of the deal, the UK has agreed to boost expenditure on medicines through the NHS. This move ensures that import taxes on these key exports will stay at zero for a duration of 36 months. This deal follows earlier threats to dramatically increase import taxes on patented pharmaceutical products, with potential rates mentioned reaching double the cost. "This agreement between the UK reinforces the global environment for innovative medicines and establishes long-overdue balance to American-British medicine commerce," a release said. Trade Impact Medicines constitute one of the Britain's largest exports to the United States, which is by far the biggest buyer for large UK drugmakers. Export figures reveal that in the year to the end of September, the UK exported drugs valued at over eleven billion pounds to the US. This figure made up nearly one-fifth of British export trade in that period. "This deal safeguards employment, stimulates funding and paves the way for the UK to emerge as a international leader for biotech and pharma," a government official stated. Detailed UK Commitments The pact entails several notable changes from the British government: Revised Affordability Limit: The UK will raise the price threshold at which it judges new treatments to be prohibitively costly by 25%. Higher Drug Budget: There is a target to double overall NHS spending on drugs from 0.3% of GDP to 0.6% over the following ten-year period. Rebate Cap: The sum pharmaceutical firms must pay back to the NHS to control costs will be capped at 15%. In the past, rebates topped 20%. Broader Context This agreement comes amid a ongoing dispute between the sector and the UK government over medicine costs and regulatory access. These tensions were exacerbated by assertions that American customers were charged significantly more for the equivalent treatments than consumers in the UK and Europe. Recently, several major manufacturing plans in the UK have been delayed or scrapped, while major funding commitments have been announced toward US facilities. A senior figure publicly accepted that the NHS had to invest a greater share on treatments, noting that its budget allocation on drugs had shrunk as a percentage of its overall budget over the last ten years.